These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12848632)

  • 21. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
    Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
    Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A; Wruble LD; Humphries TJ
    Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
    Galmiche JP; Zerbib F; Ducrottè P; Fournet J; Rampal P; Avasthy N; Humphries TJ
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1343-50. PubMed ID: 11552904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
    Archimandritis AJ; Nikolopoulou V; Kouklakis G; Paraskevas E; Avgerinos A; Tsianos E; Triantafillidis JK;
    Curr Med Res Opin; 2005 Apr; 21(4):603-10. PubMed ID: 15899110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A; Breiter J; Perdomo C; Barth J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
    Peura DA; Kovacs TO; Metz DC; Siepman N; Pilmer BL; Talley NJ
    Am J Med; 2004 Jun; 116(11):740-8. PubMed ID: 15144910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
    Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
    Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
    Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P
    J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: rabeprazole's profile in patients with gastrointestinal diseases.
    Humphries TJ; Barth J
    Aliment Pharmacol Ther; 1999 Oct; 13 Suppl 5():25-32. PubMed ID: 10555606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rabeprazole is latest entrant in proton-pump-inhibitor class.
    Miller JL
    Am J Health Syst Pharm; 1999 Oct; 56(19):1910. PubMed ID: 10554904
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
    Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
    Eggleston A; Katelaris PH; Nandurkar S; Thorpe P; Holtmann G;
    Aliment Pharmacol Ther; 2009 May; 29(9):967-78. PubMed ID: 19210493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
    Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
    Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
    Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
    Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
    Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
    Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of a proton pump inhibitor given in the early postoperative period to relieve symptoms of hiatal hernia after open heart surgery.
    Hata M; Shiono M; Sekino H; Furukawa H; Sezai A; Iida M; Yoshitake I; Hattori T; Wakui S; Taoka M; Negishi N; Sezai Y
    Surg Today; 2006; 36(2):131-4. PubMed ID: 16440158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.